CIML NK Cells With Venetoclax for AML
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this research study is to test the safety and to explore the effectiveness of infusing cytokine- induced memory-like (CIML) natural killer (NK) cells in combination with Interleukin-2 (IL-2) and standard-of-care venetoclax as a treatment for Acute Myeloid Leukemia (AML). Names of the study therapies involved in this study are: * Lymphodepleting therapy with Fludarabine and Cyclophosphamide prior to CIML NK cell infusion * CIML NK (a cellular therapy) * IL-2 (a recombinant, human glycoprotein) * Venetoclax (a selective inhibitor of BCL-2 protein)
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Postawiona diagnoza białaczki ostrej
- •Wiek co najmniej 18 lat
- •Pacjent otrzymuje leczenie wenetoklaксem i już przeszedł co najmniej jeden cykl tego leczenia
- •Posiada cechy genetyczne wskazujące na wysokie ryzyko powrotu choroby
- •Ogólny stan zdrowia pacjenta oceniony na 0-2 w skali ECOG
- •Prawidłowa funkcja wątroby, nerek i serca
- •Saturacja tlenu minimum 90% oddychając powietrzem pokojowym
- •Ujemny test ciążowy dla kobiet w wieku rozrodczym
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 24, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
Brigham and Women's Hospital
Boston, United States
Dana-Farber Cancer Institute
Boston, United States
Trial contact
Evan Chen, MD
Rizwan Romee, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/26/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.